PMID- 36456131
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20221205
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 12
DP  - 2022 Dec
TI  - Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous 
      Cell Carcinoma.
PG  - 5751-5761
LID - 10.21873/anticanres.16082 [doi]
AB  - BACKGROUND/AIM: The prognosis of recurring and metastatic head and neck squamous 
      cell carcinoma (HNSCC) is poor. Although immune checkpoint inhibitors have 
      expanded the treatment options for HNSCC, the response rates are low. 
      Alternatively, cancer vaccines and T-cell therapies are being developed. 
      Identification of useful common cancer antigens and confirmation of human 
      leukocyte antigen (HLA) class I expression are required. MATERIALS AND METHODS: 
      Immunohistochemistry analyses were performed for 10 antigens (FOXM1, TGFBI, 
      SPARC, HSP105alpha, WT1, AFP, GPC3, PP-RP, KIF20A, KM-HN-1) and HLA class I using 
      specimens of 56 surgical cases. Staining intensity, percentage of stain-positive 
      areas, and localization of staining in the tumor cells and normal tissue were 
      evaluated. RESULTS: Staining of FOXM1, TGFBI, SPARC, and HSP105alpha was more 
      predominant in tumor cells than that in normal cells. The expression rates of 
      these antigens in tumor cells were 60.7%, 58.9%, 73.2%, and 50.0%, respectively. 
      Regarding sites, the expression rates of these antigens in oral cancer were high 
      at 57.1%, 71.4%, 81.0%, and 66.7%, respectively. Furthermore, the expression of 
      HLA class I was 83.9% in all cases. Of these, 68.1% showed expression on the 
      plasma membrane. CONCLUSION: FOXM1, TGFBI, SPARC, and HSP105alpha could be useful 
      common cancer antigens, and HLA class I is expressed on the plasma membrane of 
      cancer cells in many cases. The results suggest that cancer vaccines and T-cell 
      therapy may be clinically viable options for HNSCC treatment.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Morishita, Yohei
AU  - Morishita Y
AD  - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical 
      Trial Center, National Cancer Center, Kashiwa, Japan.
AD  - Department of Head and Neck Surgery, National Cancer Center Hospital East, 
      Kashiwa, Japan.
FAU - Takenouchi, Kazumasa
AU  - Takenouchi K
AD  - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical 
      Trial Center, National Cancer Center, Kashiwa, Japan.
FAU - Sakashita, Shingo
AU  - Sakashita S
AD  - Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, 
      National Cancer Center, Kashiwa, Japan.
FAU - Matsuura, Kazuto
AU  - Matsuura K
AD  - Department of Head and Neck Surgery, National Cancer Center Hospital East, 
      Kashiwa, Japan.
FAU - Hayashi, Ryuichi
AU  - Hayashi R
AD  - Department of Head and Neck Surgery, National Cancer Center Hospital East, 
      Kashiwa, Japan.
FAU - Nakatsura, Tetsuya
AU  - Nakatsura T
AD  - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical 
      Trial Center, National Cancer Center, Kashiwa, Japan; tnakatsu@east.ncc.go.jp.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Cancer Vaccines)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (GPC3 protein, human)
RN  - 0 (Glypicans)
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - *Cancer Vaccines
MH  - Neoplasm Recurrence, Local
MH  - Immune Checkpoint Inhibitors
MH  - *Head and Neck Neoplasms/therapy
MH  - Glypicans
OTO - NOTNLM
OT  - Head and neck cancer
OT  - T cell therapy
OT  - cancer antigen
OT  - cancer vaccines
OT  - human leukocyte antigen class I
OT  - oral cancer
EDAT- 2022/12/02 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/12/01 21:13
PHST- 2022/07/30 00:00 [received]
PHST- 2022/09/27 00:00 [revised]
PHST- 2022/10/05 00:00 [accepted]
PHST- 2022/12/01 21:13 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
AID - 42/12/5751 [pii]
AID - 10.21873/anticanres.16082 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Dec;42(12):5751-5761. doi: 10.21873/anticanres.16082.